Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis
Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers curative potential to a number of older patients with acute myeloid leukemia (AML) in their first complete remission. However, there are limited data in the literature concerning post‐HCT outcomes for older patients in their second complete remission (CR2).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 24, 2017
- Source ID
- 10.1002/cncr.30567
Entities
People
- Amer Beitinjaneh
- Armin Rashidi
- Betul Oran
- Brenda M. Sandmaier
- Daniel J Weisdorf
- David A. Rizzieri
- For The Acute Leukemia Working Committee Of The Center For International Blood And Marrow Transplant Research, Aresearch Collaboration Between The National Marrow Donor Program/be The Match Registry And Themedicalcollegeofwisconsin
- Fotios V Michelis
- H. Jean Khoury
- Hailin Wang
- Hillard M Lazarus
- Mahmoud Aljurf
- Marcos de Lima
- Martin S. Tallman
- Mei‐jie Zhang
- Mohamed Kharfan‐dabaja
- Partow Kebriaei
- Richard F. Olsson
- Robert Peter Gale
- Taiga Nishihori
- Ulrike Bacher
- Vikas Gupta
- Wael Saber
- Yi‐bin Chen
- Zachariah DeFilipp
Organizations
- Duke University
- Emory University
- Fred Hutchinson Cancer Center
- H. Lee Moffitt Cancer Center & Research Institute
- Health Resources and Services Administration
- Imperial College London
- Karolinska Institutet
- Massachusetts General Hospital
- Medical College of Wisconsin
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- UH Cleveland Medical Center
- University of Miami
- University of Minnesota
- University of Texas at Austin
- University of Washington
- Uppsala University
- Washington University in St. Louis